The field of multiple myeloma prognostication is replete with studies that have shown
the value of independent predictors in determining clinical outcome. It is clear that
host factors and factors intrinsic to the cells are the ultimate determinants of prognosis.
In the immediate period after diagnosis, those factors related to the host are likely
to be more relevant, whereas with passing time factors intrinsic to the cells predominate.
At a minimum, we recommend that a comprehensive molecular cytogenetic assessment be
performed at diagnosis, together with conventional evaluation, including β2-microglobulin and albumin. In addition, information on proliferative activity of
plasma cells may be of value. The introduction of novel methods of prognostication
should be strongly considered in all clinical trials.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Multiple myeloma.N Engl J Med. 2004; 351 ([see comment][erratum appears in N Engl J Med. 2005 Mar 17;352(11):1163]): 1860-1873
- The molecular classification of multiple myeloma.Blood. 2006; 108: 2020-2028
- Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.Blood. 2002; 100: 1579-1583
- Clinical and biologic implications of recurrent genomic aberrations in myeloma.Blood. 2003; 101: 4569-4575
- Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.Blood. 2005; 106: 2837-2840
- High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.Blood. 1998; 92: 3131-3136
- Many and multiple myeloma(s).Leukemia. 2003; 17: 1943-1944
- Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma.Leukemia. 2005; 19: 1634-1642
- International staging system for multiple myeloma.J Clin Oncol. 2005; 23: 3412-3420
- Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma.Leukemia. 2003; 17: 427-436
- Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases.Leukemia. 1998; 12: 960-969
- High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.Cancer Cell. 2006; 9: 313-325
- Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome.Blood. 2007;
- In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.Blood. 2003; 101: 1520-1529
- Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.J Clin Oncol. 2005;
- Bortezomib therapy response is independent of cytogenic abnormalities in relapsed/refractory multiple myeloma.Leuk Res. 2007; 31: 779-782
- Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation.Bone Marrow Transplant. 2005;
- A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies.Cancer Genet Cytogenet. 1998; 101: 7-11
- Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement.Mayo Clin Proc. 2007; 82: 323-341
- Multiple myeloma: evolving genetic events and host interactions.Nat Rev Cancer. 2002; 2: 175-187
- Myeloma and the t(11;14)(q13;q32) represents a uniquely defined biological subset of patients.Blood. 2002; 99: 3735-3741
- The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.Am J Clin Pathol. 2000; 113: 831-837
- t(11;14) and t(4;14) translocations correlated with mature lymphoplasmocytoid and immature morphology, respectively, in multiple myeloma.Leukemia. 2003; ([this issue])
- The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.Blood. 2003; 102: 2562-2567
- Hypodiploidy is a major prognostic factor in multiple myeloma.Blood. 2001; 98: 2229-2238
- Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma.Br J Haematol. 2002; 118: 1041-1047
- Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.Leukemia. 2006; 20: 807-813
- Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.Blood. 1995; 86: 4250-4256
- Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.J Clin Oncol. 1997; 15: 2659-2666
- Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes.Blood. 1998; 91: 3366-3371
- Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.Blood. 2000; 95: 1925-1930
- Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.Blood. 2005; 106: 3553-3558
- Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy.Leukemia. 2001; 15: 981-986
- Biologic and prognostic significance of interphase FISH detection of chromosome 13 abnormalities (D13) in multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) Study.Cancer Res. 2002; 62: 715-720
- Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome.Blood. 1999; 94: 2583-2589
- Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13.Br J Haematol. 2000; 111: 1116-1117
- Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.Leukemia. 2007; 21: 143-150
- Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma.Leukemia. 2006; 20: 1610-1617
- Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.Blood. 1998; 92: 802-809
- p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.Blood. 2005; 105: 358-360
- Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions.Br J Haematol. 2004; 127: 280-284
- Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.Blood. 1996; 88: 2699-2706
- High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.Hum Mutat. 2001; 18: 212-224
- Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition some plasma cell tumors.Blood. 2005; 105: 317-323
- Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia.Clin Cancer Res. 1997; 3: 2173-2179
- Methylation of the p16INK4A gene in multiple myeloma.Br J Haematol. 1998; 101: 558-564
- Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival.Br J Haematol. 2002; 118: 1034-1040
- Methylation of p16 and p15 genes in multiple myeloma.Chin Med Sci J. 2002; 17: 101-105
- Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma.Haematologica. 2003; 88: 476-478
- Hypermethylation of p16 INK4A gene promoter during the progression of plasma cell dyscrasia.Leukemia. 2001; 15: 157-165
- Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications.Blood. 2006;
- The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma.Haematologica. 2006; 91: 1551-1554
- Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.Blood. 2005; 106: 296-303
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.Blood. 2007; 109: 2276-2284
- Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin.Blood. 1998; 91: 1732-1741
- Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.Leukemia. 2006; 20: 2034-2040
- Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma.Cancer Cell. 2007; 12: 131-144
- Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.Blood. 2007; 109: 3177-3188
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study.Blood. 2006;
- The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.Br J Haematol. 2004; 125: 64-68
- Clinical implication of centrosome amplification in plasma cell neoplasm.Blood. 2006; 107: 3669-3675
- Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.Blood. 1999; 93: 1032-1037
- Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma.Am J Hematol. 1989; 30: 195-200
- Immunophenotype and DNA content of myeloma cells in primary plasma cell leukemia.Am J Hematol. 1992; 39: 159-162
- Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.Br J Haematol. 1995; 90: 106-112
- A new staging system for multiple myeloma based on the number of S-phase plasma cells.Blood. 1995; 85: 448-455
- Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?.Leuk Lymphoma. 1999; 35: 83-89
- Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma.Blood. 2004; 104: 2661-2666
- Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.Blood. 1993; 81 ([see comments]): 3382-3387
- The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis.Br J Haematol. 1996; 94: 76-81
- Immunophenotype and DNA cell content in multiple myeloma.Baillieres Clin Haematol. 1995; 8: 735-759
- Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients.Int J Cancer. 2004; 112: 884-889
- Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases.Am J Clin Pathol. 1987; 87: 342-355
- Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.J Clin Oncol. 1999; 17: 1551-1557
- Plasmablastic morphology—an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group.Blood. 1998; 91: 2501-2507
- Multiple myeloma: ‘early’ plasma cell phenotype identifies patients with aggressive biological and clinical characteristics.Br J Haematol. 1993; 85: 504-513
- Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.Br J Haematol. 1991; 77: 185-190
- Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.Blood. 1994; 84: 2597-2603
- Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization.Cancer Res. 1995; 55: 3647-3653
- CD28, a marker associated with tumoral expansion in multiple myeloma.Clin Cancer Res. 1998; 4: 1521-1526
Mateo G, Corral M, Almeida J, et al. Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma. 2003;88:1013–21.
- Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens.Leuk Lymphoma. 2004; 45: 61-65
- Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.Haematologica. 2004; 89: 547-551
- Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression.Blood. 2001; 98: 187-193
- The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies.Clin Cancer Res. 2004; 10: 6544-6550
- Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma.Blood. 2001; 97: 1508-1510
- Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.Cancer Immun. 2003; 3: 9
- The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells.Eur J Immunol. 2000; 30: 803-809
- Genes encoding tumor-specific antigens are expressed in human myeloma cells.Blood. 1999; 94: 1156-1164
- SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.J Immunother (1997). 2005; 28: 564-575
- The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy.Haematologica. 2006; 91: 1234-1240
- Phenotypic characterization of the human myeloma cell growth fraction.Blood. 2005; 105: 4845-4848
- Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6.Blood. 1998; 92: 3887-3897
- Increased susceptibility to apoptosis in CD45(+) myeloma cells accompanied by the increased expression of VDAC1.Oncogene. 2006; 25: 419-429
- The transmembrane protein-tyrosine-phosphatase CD45 is associated with decreased insulin-receptor signaling.J Biol Chem. 1996; 271: 755-760
- CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations.Leukemia. 2005; 19: 1466-1470
- Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.Am J Pathol. 1998; 152: 1655-1665
- Phenotypic difference of normal plasma cells from mature myeloma cells.Blood. 1993; 81: 2658-2663
- Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.J Clin Oncol. 2005; 23: 5668-5674
- Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.Blood. 2002; 100: 3095-3100
- Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.Blood. 2002; 99: 1853-1856
- Prognostic features of multiple myeloma.Best Pract Res Clin Haematol. 2005; 18: 569-583
- The adverse prognostic impact of advanced age in multiple myeloma.Leuk Lymphoma. 2005; 46: 951-966
- Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.Blood. 2003; 102: 69-77
- Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.Blood. 2000; 95: 7-11
- Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach.Crit Rev Oncol Hematol. 2005; 55: 231-240
- Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years.Br J Haematol. 1996; 93: 345-351
- Age is not a prognostic variable with autotransplants for multiple myeloma.Blood. 1999; 93: 51-54
- Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years.Br J Haematol. 2001; 114: 600-607
- Evaluation of race as a prognostic factor in multiple-myeloma—An ancillary of Southwest-Oncology-Group Study 8229.J Clin Oncol. 1996; 14: 974-977
- Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma.Bone Marrow Transplant. 2006; 37: 1099-1102
- High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.J Clin Oncol. 2000; 18: 2843-2851
- Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma.Cancer Genet Cytogenet. 2002; 137: 43-48
- Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination.J Med Genet. 2002; 39: 900-905
- Haplotypes in the tumour necrosis factor region and myeloma.Br J Haematol. 2005; 129: 358-365
- Haplotypic structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma.Cancer Lett. 2007; 246: 92-99
- Genetic variations in benzene metabolism and susceptibility to multiple myeloma.Leuk Res. 2006;
- Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.Blood. 2002; 100: 2263-2265
- Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma.Blood. 2003; 102: 2345-2350
- Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(−) compartment.Blood. 2001; 98: 2817-2827
- The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma.Leukemia. 1997; 11: 1312-1317
- Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial.Blood. 1997; 90: 340-345
- Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients.Blood. 2001; 98: 23-28
- Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma.Blood. 1996; 88: 1780-1787
- A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.Cancer. 1975; 36: 842-854
- Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials.Blood. 2006; 108: 2013-2019
- Multiple myeloma: beta-2-microglobulin is not a useful follow-up parameter.Acta Haematol. 1989; 82: 122-125
- Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders.J Clin Oncol. 1984; 2: 51-57
- Unexpected normal serum beta-microglobulin (B2M) levels in multiple myeloma.Anticancer Res. 1987; 7: 513-515
- Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.Br J Haematol. 1990; 75: 506-510
- Monoclonal gammopathies: new approaches to clinical problems in diagnosis and prognosis.Blood Rev. 1989; 3: 222-236
- Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.Acta Haematol. 1997; 97: 191-195
- Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.Blood. 1989; 73: 517-526
- Independent prognostic value for serum soluble interleukin-6 receptor (sIL-6R) in Eastern Cooperative Oncology Group (ECOG) myeloma trial E9487.Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1993; 12 ([meeting abstract])
- Independent prognostic value for plasma cell labeling index (PCLI), immunofluorescence microscopy plasma cell percent (IMPCP), beta 2-microglobulin (B2M), soluble interleukin-6 receptor (sIL-6R), and c-reactive protein (CRP) in myeloma trial E9487.Blood. 1994; 84 ([meeting abstract])
- Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group.Br J Haematol. 1996; 92: 370-374
- Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias.Br J Haematol. 1995; 91 ([see comments]): 116-120
- C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.Blood. 1992; 80: 733-737
- Acute phase proteins and prognosis in multiple myeloma.Br J Haematol. 1993; 83: 595-601
- Serum syndecan-1: a new independent prognostic marker in multiple myeloma.Blood. 2000; 95: 388-392
- Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival.Br J Haematol. 2005; 130: 542-548
- Prognostic factors and classification in multiple myeloma.Br J Cancer. 1989; 59: 113-118
- Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma.Ann Oncol. 2005; 16: 1824-1828
- Role of MRI for the diagnosis and prognosis of multiple myeloma.Eur J Radiol. 2005; 55: 56-63
- Whole-body (18)F-FDG PET identifies high-risk myeloma.J Nucl Med. 2002; 43: 1457-1463
- Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma.Br J Haematol. 2002; 117: 133-135
- Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients.Br J Haematol. 2000; 109: 24-29
- Bone remodelation markers are useful in the management of monoclonal gammopathies.Hematol J. 2004; 5: 480-488
- Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen.Blood. 1997; 90: 3743-3750
- Systemic matrix metalloproteinase-9 (MMP-9) levels as prognostic indexes of bone disease in patients with multiple myeloma.Clin Chem Lab Med. 2006; 44 ([author reply: 233]): 232
- Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease.Clin Chem Lab Med. 2005; 43: 934-938
- Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.Cancer Res. 2005; 65: 1700-1709
- Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.Blood. 2003; 102: 1064-1069
- Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.Blood. 2005; 105: 4784-4791
- Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients.Br J Haematol. 1994; 88: 117-121
- Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma.ASCO Annual Meeting Proceedings Part I. 2006; 24 ([abstract: 1])
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.Lancet. 2006; 367: 825-831
- High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.N Engl J Med. 2003; 348: 1875-1883
- A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome.N Engl J Med. 1996; 335: 91-97
- Impact of complete remission with intensive therapy in patients with responsive multiple myeloma.Bone Marrow Transplant. 2001; 27: 1037-1043
- Total therapy with tandem transplants for newly diagnosed multiple myeloma.Blood. 1999; 93: 55-65
- Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients.Br J Haematol. 2000; 109: 438-446
- Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.Cancer. 2006; 106: 1958-1966
- Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.J Clin Oncol. 2004; 22: 1857-1863
- Thalidomide and hematopoietic-cell transplantation for multiple myeloma.N Engl J Med. 2006; 354: 1021-1030
- Serum test for assessment of patients with Bence Jones myeloma.Lancet. 2003; 361: 489-491
- International uniform response criteria for multiple myeloma.Leukemia. 2006; 20: 1467-1473
Article info
Identification
Copyright
© 2007 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
